IL 31 Mechanism of Action and Clinical Implications for Prurigo Nodularis

This is the second episode of a two-part miniseries, "IL-31 Inhibition for Treatment of Prurigo Nodularis" series, supported by an educational grant from Galderma. Hosted by expert dermatologist and neuroscientist Dr. Sarina Elmariah, MD, PhD, MPH, this episode, "IL-31 Mechanism and Clinical Implications for PN", featuring Dr. Shawn Kwatra, discusses the following topics: • Mechanism of action for IL-31 inhibitor nemolizumab • Clinical safety and efficacy data for nemolizumab for treatment of PN • Strategies for prescribing IL-31 inhibitors in clinical practice • Pearls for patient selection and addressing treatment challenges